These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24890202)

  • 1. Relapsing-remitting severe generalized muscular weakness after botulinum toxin treatment for hyperhidrosis.
    Chiarello D; Piombo M; Corbetto M; Di Pino G; Assenza G; Capone F; Di Lazzaro V
    Muscle Nerve; 2014 Sep; 50(3):456-7. PubMed ID: 24890202
    [No Abstract]   [Full Text] [Related]  

  • 2. Generalized neurological symptoms following treatment of focal hyperhidrosis with botulinum toxin A.
    Kouris A; Agiasofitou E; Gregoriou S; Sofouri E; Kontochristopoulos G; Panagopoulos G
    Int J Dermatol; 2014 Nov; 53(11):e544-7. PubMed ID: 25209010
    [No Abstract]   [Full Text] [Related]  

  • 3. Muscle weakness in treatment of palmar hyperhidrosis with botulinum toxin type a: can it be prevented?
    Kouris A; Vavouli C; Markantoni V; Kontochristopoulos G
    J Drugs Dermatol; 2014 Nov; 13(11):1315-6. PubMed ID: 25607695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Writer's block: "texting" impairment as a complication of botulinum toxin type A therapy for palmar hyperhidrosis.
    Lehman JS
    Arch Dermatol; 2011 Jun; 147(6):752. PubMed ID: 21690551
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic effect of local and small-dose botulinum toxin injection to unmask subclinical myasthenia gravis.
    Iwase T; Iwase C
    Graefes Arch Clin Exp Ophthalmol; 2006 Mar; 244(3):415-6. PubMed ID: 16175373
    [No Abstract]   [Full Text] [Related]  

  • 6. Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months.
    Frasson E; Brigo F; Acler M; Didonè G; Vicentini S; Bertolasi L
    Arch Dermatol; 2011 Jan; 147(1):122-3. PubMed ID: 21242408
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and self-reported efficacy of botulinum toxin for adult spasticity in current clinical practice: a prospective observational study.
    Muller F; Cugy E; Ducerf C; Delleci C; Guehl D; Joseph PA; Burbaud P; Dehail P
    Clin Rehabil; 2012 Feb; 26(2):174-9. PubMed ID: 21937525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contralateral weakness following botulinum toxin for poststroke spasticity.
    Thomas AM; Simpson DM
    Muscle Nerve; 2012 Sep; 46(3):443-8. PubMed ID: 22907238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis.
    Baumann LS; Halem ML
    Arch Dermatol; 2003 Feb; 139(2):226-7. PubMed ID: 12588237
    [No Abstract]   [Full Text] [Related]  

  • 10. Inverse psoriasis and hyperhidrosis of the axillae responding to botulinum toxin type A.
    Saber M; Brassard D; Benohanian A
    Arch Dermatol; 2011 May; 147(5):629-30. PubMed ID: 21576592
    [No Abstract]   [Full Text] [Related]  

  • 11. Botulinum toxin type A and B improve quality of life in patients with axillary and palmar hyperhidrosis.
    Rosell K; Hymnelius K; Swartling C
    Acta Derm Venereol; 2013 May; 93(3):335-9. PubMed ID: 23053164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myaesthenia gravis exacerbation caused by axillary injection of botulinum toxin A for treatment of hyperhidrosis.
    El-Heis S; Burke G; Gibb W; Ardern-Jones MR
    Clin Exp Dermatol; 2017 Apr; 42(3):357-359. PubMed ID: 28111784
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of compensatory hyperhidrosis with botulinum toxin type A.
    Belin EE; Polo J
    Cutis; 2003 Jan; 71(1):68-70. PubMed ID: 12553633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of axillary hyperhidrosis with botulinum-A toxin.
    Salmanpoor R; Rahmanian MJ
    Int J Dermatol; 2002 Jul; 41(7):428-30. PubMed ID: 12121560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The place of botulinum toxin type A in the treatment of focal hyperhidrosis.
    Lowe N; Campanati A; Bodokh I; Cliff S; Jaen P; Kreyden O; Naumann M; Offidani A; Vadoud J; Hamm H
    Br J Dermatol; 2004 Dec; 151(6):1115-22. PubMed ID: 15606505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Safety and Dosing of OnabotulinumtoxinA: A Prospective, Observational Study.
    Wein T; Jog M; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
    Can J Neurol Sci; 2019 Nov; 46(6):742-752. PubMed ID: 31256770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of palmar hyperhidrosis with botulinum neurotoxin a.
    Mannava S; Mannava KA; Nazir OF; Plate JF; Smith BP; Koman LA; Tuohy CJ
    J Hand Surg Am; 2013 Feb; 38(2):398-400. PubMed ID: 23267759
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperhidrosis of face and scalp: repeated successful treatment with botulinum toxin type A.
    Komericki P; Ardjomand N
    Indian J Dermatol Venereol Leprol; 2012; 78(2):201-2. PubMed ID: 22421660
    [No Abstract]   [Full Text] [Related]  

  • 19. How to save botulinum toxin A in the treatment of focal axillary hyperhidrosis.
    Bechara FG; Sand M; Hoffmann K
    Dermatology; 2006; 213(4):356. PubMed ID: 17135747
    [No Abstract]   [Full Text] [Related]  

  • 20. Problems with botulinum toxin treatment in mitochondrial cytopathy: case report and review of the literature.
    Gioltzoglou T; Cordivari C; Lee PJ; Hanna MG; Lees AJ
    J Neurol Neurosurg Psychiatry; 2005 Nov; 76(11):1594-6. PubMed ID: 16227561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.